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Abstract: Hypothyroidism, characterised by low/normal free thyroxine (FT4) and free tri-iodothyronine 
(FT3) with elevated thyroid-stimulating hormone (TSH), is a well-known complication of nephrotic syn-
drome (NS). This is a common feature of primary and secondary glomerular diseases and comprises loss 
of protein in the urine and increased urinary excretion of thyroid hormones and thyroxine-binding globu-
lin. With a normal thyroid reserve, this scenario is associated with the development of subclinical hypo-
thyroidism, with a slight increase in TSH and normal free fractions. However, with a low thyroid reserve 
the transition toward overt hypothyroidism is almost inevitable, affecting morbidity and mortality. As T4 
replacement is a cheap and well-established treatment to achieve a stable hormone status in different 
types of thyroid deficiency, it is essential to recognise and appropriately treat this condition. In this article 
we summarise the evidence on this nephro-endocrine disorder in humans and focus on diagnostic and 
therapeutic strategies. 
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INTRODUCTION 
 Despite the considerable available data, the exact preva-
lence of hypothyroidism and subclinical hypothyroidism in 
adult patients with nephrotic proteinuria is still unclear [1]. 
Surprisingly, the 2012 clinical practice guidelines for glome-
rulonephritis do not mention hypothyroidism as a complica-
tion of glomerular disease [2], leading to a risk of its serious 
underdiagnosis. However, the latest American guidelines for 
the treatment of hypothyroidism underline the role of severe 
urinary protein loss in increasing replacement therapy re-
quirements [3]. For these reasons, this review focuses on the 
most recent evidence and information on this topic.  
PATHOPHYSIOLOGY  
 The hypothalamic-pituitary-thyroid axis is a complex 
endocrine system which controls the production of thyroid 
hormones. The paraventricular nucleus of the hypothalamus 
secretes thyrotropin-releasing hormone, which in turn leads 
to pituitary secretion of thyroid-stimulating hormone (TSH). 
TSH binds to thyroid receptors and stimulates the biosynthe-
sis and secretion of thyroxine (T4) and tri-iodothyronine (T3) 
into the plasma [4]. The steps involved are: (i) transport of 
iodine into the thyroid gland; (ii) iodination of thyroglobulin 
tyrosyl residues, resulting in synthesis of either mono-
iodinated tyrosine (MIT) or di-iodinated tyrosine (DIT),  
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incorporated into thyroglobulin; (iii) coupling of iodotyrosi-
nes to form the hormonally active iodothyronines: two DITs 
lead to the formation of T4, while one DIT plus one MIT lead 
to T3 synthesis.  
 The hormones thus formed are held in thyroglobulin, the 
major component of intrafollicular colloid. The active thy-
roid hormones free T3 (FT3) and free T4 (FT4) are released 
through the hydrolysis of thyroglobulin by a thyroid protease 
and peptidases [5]. About 85 g of T4 are secreted by the 
thyroid gland every day, while only 20% of the 33 g of 
normally circulating T3 derives from direct thyroid release. 
The rest (80%) is produced by a peripheral T4 deiodination 
reaction involving a specific enzyme which removes one 
iodine from the outer ring of T4 [6]. Thyroid hormones are 
linked with the plasma binding proteins thyroxine-binding 
globulin (TBG), transthyretin and human serum albumin 
during transport; these account, respectively, for 74, 11 and 
15% of all T4 binding. The high affinities of the binding pro-
teins result in a slow clearance and prolonged half-life of 
thyroid hormones in the circulation [7].  
 Upon release to the target tissues through different carri-
ers, thyroid hormones undergo cytosolic enzymatic reac-
tions, involving T4 deiodination by iodothyronine deio-
dinases (types 1, 2 and 3) [8]. The selective removal of an 
iodine atom from the phenolic (outer) ring produces the bio-
logically active hormone T3, whereas its removal from the 
tyrosyl (inner) ring generates the inactive metabolite reverse 
T3. These reactions play a crucial role in the homeostasis of 
thyroid hormones [4]. The final step of this cascade is the 
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interaction between active hormones and their nuclear thy-
roid hormone receptors, which modulates gene transcription 
in response to hormones [9].  
 While hypothyroidism is defined as high serum TSH 
with concomitant low levels of FT3 and FT4, subclinical hy-
pothyroidism involves elevated TSH despite normal serum 
levels of FT3 and FT4 [10]. The American Association of 
Clinical Endocrinologists/American Thyroid Association 
recommends treating the latter condition only in sympto-
matic patients positive for thyroid antibodies or with cardio-
vascular risk factors [3]. There are no clinical outcome data 
supporting levothyroxine (LT4) treatment in patients with 
serum TSH levels between 2.5 and 4.5 mIU/L [3]. It is rec-
ommended that all patients with subclinical hypothyroidism 
and a TSH >10 mIU/L be treated with LT4, as they have 
higher all-cause mortality [11]. Hypothyroidism and moder-
ate subclinical hypothyroidism are associated with increased 
all-cause mortality independent of coronary heart disease 
[11] and with increased risk of heart failure [12].  
 According to most recent guidelines, NS in adults is de-
fined as a complex alteration of the glomerular filtration bar-
rier which results in proteinuria >3.5 g/24 h, hypoalbu-
minaemia (<3 g/dL), peripheral oedema and often hyper-
lipidaemia. Heavy proteinuria (>3.5 g/24 h) without the 
clinical features of NS is commonly referred to as isolated 
nephrotic proteinuria [2]. This specific presentation of kid-
ney disease may occur in a wide variety of primary and sys-
temic diseases and its incidence is estimated to be three new 
cases per 100 000 each year [13]. In adults, the main causes 
seem to be primary glomerulonephritis (in particular mem-
branous nephropathy and focal segmental glomerulosclero-
sis), while approximately 30% of cases are due to a systemic 
disease such as diabetes mellitus, systemic lupus erythema-
tosus or amyloidosis [14-17]. Complications in NS may be 
part of the disease itself or develop as a consequence of its 
treatment [18]. The loss of proteins in the urine changes their 
plasma concentrations, causing secondary insufficiency and 
impairment of metabolic functions [19].  
 Abnormal thyroid function is a not uncommon complica-
tion of nephrotic diseases. Its pathophysiology was first in-
vestigated in 1926, when Albert A. Epstein postulated a 
common aetiology for hypothyroidism and nephrotic state 
[20]. It was later clarified that LT4 is ineffective in the treat-
ment of proteinuric diseases and that hypercholesterolaemia 
in nephrosis is not only related to hypothyroidism, but above 
all to the urinary loss of lipoprotein binding proteins [21, 
22]. In fact, although the exact cause appears to be complex, 
dysthyroidism in NS has been explained by the loss of hor-
mone binding proteins occurring in this setting [23]. The 
large fraction of thyroid hormones bound to plasma proteins 
pass the glomerular filtration barrier and are lost in urine, as 
they are only partly reabsorbed in the proximal tubule by 
megalin and cubilin complexes [24]. The progressive tubular 
defect typically seen in chronic proteinuric diseases may 
then exacerbate the pre-existing decline of circulating thy-
roid hormone.  
 Small observational studies of the renal metabolism of 
FT3 and FT4 conducted in healthy subjects have demon-
strated that FT4 is usually mostly reabsorbed by the tubules, 
while FT3 is just secreted [25, 26]. A tubular dysfunction 
may therefore affect FT3 and FT4 metabolism, worsening the 
primary glomerular insufficiency. Although evidence of 
urine excretion of T4, T3 and TBG in NS is limited, most 
studies have confirmed the high excretion of T4 and T3 dur-
ing nephrosis [27]. Furthermore, there was a positive correla-
tion between 24 h proteinuria and urinary concentration of 
T4, T3 and TBG in patients with NS, while serum TSH was 
negatively correlated with albumin [28]. In other words, the 
increase in TSH is correlated with the degree of proteinuria, 
and is thus a possible predictor of worsening kidney failure 
[1]. Furthermore, in some clinical trials hypothyroidism was 
associated with oedema onset and there was a remission of 
protein loss upon relief of the hypothyroidism [29]. How-
ever, as recent literature confirms, most patients with NS 
have subclinical hypothyroidism, with normal FT3 and FT4 
levels and elevated TSH compared with basal values [30]. 
This indicates that the thyroid is normally able to compen-
sate for the urinary loss of hormones and patients remain 
euthyroid. However, if a primary glandular disease coexists, 
overt hypothyroidism can develop, leading to an increase in 
exogenous levothyroxine requirements [31].  
 In any case, the hormonal thyroid profile in nephrotic 
states is highly variable and hypothyroidism is known to 
have different degrees of severity [32]. In consequence, 
dysthyroidism in nephrotic kidney diseases is likely to have a 
more complicated pathophysiology. In addition, TSH is a 
low molecular weight protein (28.5 kDa), which can be lost 
in urine in patients with glomerular disease. Increased uri-
nary excretion of TSH has been reported in some small-
caseload studies, suggesting another possible explanation for 
non-constant onset of hypothyroidism among these patients 
[33]. Obviously, the difference in proteinuria selectivity may 
itself further confuse the hormone profiles, producing differ-
ent degrees of hypothyroidism in patients with different 
glomerulopathies [34]. Furthermore, it has already been 
shown that a lower T3 level correlates with a higher urinary 
amount of T4. This might be explained by a decreased pe-
ripheral conversion of T4 to T3, suggesting a possible reason 
for the various presentations [32].  
 The considerable impact of hypothyroidism in nephrotic 
diseases could also be related to the concomitant presence of 
any acute and/or chronic renal impairment. Elevated serum 
creatinine and reduced glomerular filtration rate have been 
associated with subclinical hypothyroidism [35]. The patho-
physiological mechanisms underlying this association were 
thought to be the decline of renal plasma flow, promoted by 
the imbalance between stroke volume and peripheral resis-
tance [36], hyperlipidaemia [37] and the effects of paracrine 
and endocrine mediators such as insulin-like growth factor 
type 1 and vascular endothelial growth factor [30]. Further-
more, an interconnection between thyroid dysfunction and 
renal impairment has been observed in several case series 
where complete remission of hypothyroidism was achieved 
only on reaching end stage renal disease [38, 39].  
 Another point to be clarified with regard to NS and 
dysthyroidism is the key role played by altered iodine me-
tabolism in proteinuric diseases [40]. Briefly, non-
autoimmune hypothyroidism in NS cannot be explained by 
the substantial urinary excretion of T4, T3 and TBG alone. 
An increased urinary concentration of thyroid hormones and 
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their carriers has been observed in various kinetic and clini-
cal studies, demonstrating not only a correlation between 
hypothyroidism and the degree of nephrosis but also a close 
interconnection with the remission of these conditions. How-
ever, several other factors may influence the degree of 
dysthyroidism in this setting, including thyroid performance 
and factors influencing hormone biosynthesis, impairment of 
tubular function and the effect of kidney dysfunction on T4-
T3 peripheral conversion. 
WHY SCREENING FOR SUBCLINICAL HYPOTHY-
ROIDISM SHOULD BE PERFORMED IN NS 
 The role of hypothyroidism in reducing the glomerular 
filtration rate, changing water homeostasis and, conse-
quently, causing hyponatraemia is well known [30]. It is not 
uncommon that patients with thyroid hormone deficiency 
suffer from generalised oedema, primarily due to a reduction 
in free water clearance [41]. Similarly, oedema, essentially 
caused by sodium retention and a drop in plasma oncotic 
pressure, is a common clinical manifestation of NS [42]. 
Water retention normally worsens renal function in patients 
with primary glomerulonephritis and patients are usually 
asked to restrict their dietary fluid and sodium intake and 
take a diuretic therapy [43]. It is therefore very important to 
bear in mind that if a nephrotic glomerular disease is accom-
panied by hypothyroidism, the severe urinary loss of proteins 
may exacerbate fluid retention, which may be difficult to 
resolve if the treatment of hypothyroidism is delayed.  
 Finally, it has been demonstrated that normalising T3 and 
T4 concentrations with replacement therapy also preserves 
renal function in patients with a kidney disease and subclini-
cal hypothyroidism, and is an independent predictor of renal 
outcome [44]. For this reason, even though there are no spe-
cific recommendations for thyroid screening in patients with 
NS, we suggest thyroid function be screened not only in pa-
tients with pre-existing thyroid disease but also in those with 
no history of dysthyroidism. Earlier identification of thyroid 
hormone abnormalities may improve the global management 
of nephropathic patients and their comorbidities. In particu-
lar, the close relation between hypothyroidism and cardio-
vascular disease has already been investigated. Thyroid hor-
mones seem to have a direct action on myocardial and vascu-
lar function; they can influence endothelial dysfunction, 
blood pressure control and dyslipidaemia [45, 46]. Further-
more, thyroid deficiency is linked to abnormalities of cardiac 
myocytes and vascular smooth muscle cells and may inter-
fere with the actions of cardiologic and lipid-lowering thera-
pies [47]. 
WHEN A SUPPLEMENT THERAPY SHOULD BE 
CONSIDERED 
 The standard treatment for hypothyroidism is LT4, thanks 
to its great efficacy, simple once-daily oral administration 
and fast resolution of the signs and symptoms of hypothy-
roidism in the majority of patients (in 6 weeks at most) [48]. 
However, the treatment fails to restore thyroid function in a 
small part (10-15%) of patients, for whom LT3+LT4 combi-
nation therapy is suggested.  
 Recent advances in the understanding of thyroid hormone 
physiology show that genetic variation in deiodinases [49] or 
in thyroid hormone transporters [50] may be partly responsi-
ble for this difference. The clinician’s goals must be to re-
solve hypothyroid signs and symptoms and normalise serum 
thyroid hormone concentrations (TSH, FT3 and FT4, with 
TSH as the marker of replacement treatment adequacy) 
while avoiding overtreatment (iatrogenic thyrotoxicosis), 
especially in selected subpopulations (elderly, cardiopathic, 
etc.). An optimal and consistent absorption is achieved only 
when LT4 is taken either 60 min before breakfast or at bed-
time (3 or more hours after the evening meal) and preferably 
apart from other potentially interfering medications and sup-
plements [51]. Co-administration with food is likely to im-
pair levothyroxine absorption [52], but it is also important to 
consider patient adherence: although a fasting regimen may 
promote absorption, if administration 1 h before breakfast is 
unfeasible, 30 min before breakfast may also be reasonable.  
 The standard of choice of the minimum effective dose for 
hypothyroid patients could depend on various different fac-
tors, and should ideally be tailored to the patient: actual or 
ideal body weight, TSH goal, aetiology of hypothyroidism, 
degree of serum TSH elevation, pregnancy and age. The 
dose is generally calculated as 1.6 - 1.8 g/kg of actual body 
weight [48, 53, 54]. In some cases, higher doses are required, 
especially in patients with little residual thyroid function 
[55]: from 2.0 - 2.1 g/kg during primary hypothyroidism, 
after Basedow ablation or in athyreotic patients [56] to 2.1 - 
2.7 g/kg in patients with thyroid cancer [57]. Hypothyroid 
women taking LT4 typically require a dose increase early in 
the first trimester of pregnancy [58]. This challenge is re-
quired not only because of the well-known requirement for 
thyroid hormone to develop the fetus’ neural tube, but also 
because of the increased risk of autoimmune kidney disease 
(e.g. glomerulonephritis) during this period [51].  
 The replacement LT4 dose required to normalise TSH 
tends to decrease with age [53]. Experts advise ‘starting low 
and going slow’, especially in elderly patients and those with 
cardiovascular disease, to avoid precipitating cardiac events 
[59]. Generally, after initiation of the calculated dose, ad-
justments of 12.5 - 25 g/day could be made, based on se-
rum TSH. TSH should then be retested at 4 - 6 weeks and 4 - 
6 months to enable dose adjustment as necessary, and then 
monitored yearly [51].  
 Unfortunately, as yet there are no clinical data on the 
initiation of replacement therapy with LT4 in patients with 
NS and subclinical and/or overt hypothyroidism. In fact, 
although the latest American Thyroid Association guidelines 
suggest performing thyroid function assessment during NS, 
they lack any recommendations on dosing, timing and spe-
cific adjustments [60].  
HOW CAN HYPOTHYROIDISM BE TREATED 
 LT4 is generally prescribed worldwide in the form of 
tablets, although recent data suggest that gelatin capsules or 
oral liquid formulations may have a more favourable absorp-
tion profile in selected circumstances. Due to the lack of 
randomised controlled trials the use of these different prepa-
rations cannot currently be recommended. A switch to a gel 
capsule or liquid formulation might be worth considering in 
the rare event of putative allergies to excipients. An alterna-
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tive approach when poor absorption is suspected is to in-
crease the LT4 tablet dose [51].  
 The gelatin capsule formulation contains liquid LT4 [61] in 
contrast to standard solid LT4 tablets: this enables fast, effi-
cient dissolution, even at a low pH [62]. Some studies found 
that capsules are better absorbed when taken with coffee or 
proton pump inhibitors [63], allowing suppression of serum 
TSH in patients who did not reach euthyroidism with standard 
LT4 tablets [64]. A retrospective uncontrolled trial described 
lower serum TSH concentrations when switching from tablets 
to soft gel capsules of the same dose of LT4 [65].  
 A liquid LT4 formulation has also been proposed. Recent 
data suggested that this formulation could be better absorbed 
than tablets in cases of malabsorption (e.g. following bariat-
ric surgery) or in patients taking LT4 during breakfast [66]. 
Due to its 28% ethanol content, it is not recommended dur-
ing pregnancy and breastfeeding or in children and high-risk 
patients [66]. For patients unable to take oral medications, 
intravenous administration could be an alternative, with a 
conversion factor of 75% with respect to the oral dose. LT4 
absorption with food was calculated as 64% compared with 
80% in the fasting state [52]. 
  The different pharmacological properties are summa-
rised in Table 1. Briefly, although patients with NS show 
specific thyroid hormone profile changes, to the best of our 
knowledge no prospective studies have assessed which for-
Table 1. Pharmacological properties of different levothyroxine preparations. 
 Half-life (h) Main Site of Metabolism Main Contraindications Possible Advantages Possible Dosage (g) 
Tablets ~ 190 
80% peripheral deiodination 
20% hepatic metabolism 
- Hypersensitivity 
- Adrenal insufficiency 
- Hypopituitarism 
- Thyrotoxicosis 
 
25 
50 
75 
100 
125 
150 
175 
200 
Gelatin capsules ~ 190 
80% peripheral deiodination 
20% hepatic metabolism 
- Hypersensitivity 
- Adrenal insufficiency 
- Hypopituitarism 
- Thyrotoxicosis 
Better absorption 
during consumption 
with coffee or PPIs 
13 
25 
50 
75 
88 
100 
112 
125 
137 
150 
175 
200 
Liquid formula-
tions 
~ 190 
80% peripheral deiodination 
20% hepatic metabolism 
- Hypersensitivity 
- Adrenal insufficiency 
- Hypopituitarism 
- Thyrotoxicosis 
- Pregnancy/ breastfeeding 
- Children 
- High-risk patients 
Better absorption in 
case of malabsorption 
or in patients taking 
therapy during break-
fast 
 25 
 50 
 75  
 100 
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mulation should be preferred to reach euthyroid status as 
quickly as possible. The only available recommendations 
originate from a handful of case reports and cannot be con-
sidered as reliable.  
CONCLUSIONS 
 The increased prevalence of hypothyroidism and sub-
clinical hypothyroidism in patients with proteinuria is now 
well known. However, the pathophysiological mechanisms 
underlying this condition are not completely understood. It is 
still unclear if hypothyroidism plays a key role in the course 
of kidney disease or is an innocent bystander. What does 
seem to be clear is the worse quality of life and poor progno-
sis of NS patients with hypothyroidism. Thyroid function in 
patients with NS should thus be assessed as soon as possible, 
in order to treat this potential complication. Euthyroidism 
can now be restored by simple and versatile pharmacological 
treatment, tailored to the patient. Further studies are needed 
to establish the prevalence and diagnostic challenges of hy-
pothyroidism in the course of NS, to find reliable new thy-
roid function biomarkers in kidney proteinuric disease and to 
establish the best replacement therapy.  
LIST OF ABBREVIATIONS  
DIT = Di-iodinated tyrosine  
FT3 = Free T3  
FT4 = Free T4  
LT4 = Levothyroxine  
MIT = Mono-iodinated tyrosine  
NS = Nephrotic syndrome  
T3 = Tri-iodothyronine  
T4 = Thyroxine  
TBG = Thyroxine-binding globulin  
TSH = Thyroid-stimulating hormone  
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